Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Acquisitions & Divestments (2024)

Harvard Bioscience (HBIO) reported Change in Acquisitions & Divestments of $1.4 million for Q3 2024, little changed on a QoQ basis from $1.4 million in Q2 2024.

Harvard Bioscience (HBIO) has 1 years of Change in Acquisitions & Divestments data on file, last reported at $1.4 million in Q3 2024.

  • Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $1.4 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $1.4 million (down 26.12% YoY) and the FY2024 annual result came in at $1.9 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments was little changed at $1.4 million in Q3 2024 per HBIO's latest filing, from $1.4 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.4 million in Q2 2024 and bottomed at $495000.0 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 1.40 Mn
Sep 30, 2024 1.40 Mn
Jun 30, 2024 1.40 Mn
Jun 30, 2024 1.40 Mn
Mar 31, 2024 495,000.00
Mar 31, 2024 495,000.00